Date lodged: 1 June 2018
To ask the Scottish Government, in the light of the US National comprehensive clinical updated guidelines on using F-18 fluviclovivine (Axumin) in diagnostic imaging in men with recurrent prostate cancer, whether it will recommend that clinicians should consider using Axumin in positronic emission tomography, computed tomography or magnetic resonance imaging in helping to determine the best treatment.
Answered by: Shona Robison 12 June 2018
The Scottish Health Technologies Group (SHTG) assesses the effectiveness and proven benefit to patients of new technologies, and they advise NHS Scotland where there is a convincing evidence base.
In 2017, SHTG found limited evidence supporting the use of Axumin for the detection of a suspected recurrent prostate cancer. The evidence base will be reviewed again in 2019, if not sooner should substantial new evidence become available.